Androgenic facial masculinization occurs through three primary pathways: androgen receptor-mediated osteoblast proliferation in the mandible and maxilla, DHT-driven chondrocyte hypertrophy in nasal and auricular cartilage, and increased sebaceous gland activity with periorbital fat redistribution. The dose-response curve is nonlinear—supraphysiological testosterone (500+ mg weekly) yields measurably more pronounced mandibular widening and brow ridge prominence than replacement dosing (100–150 mg weekly), but the timeline extends over 18–36 months for bone remodeling versus 8–16 weeks for soft tissue changes.
The masculinizing effects of exogenous androgens on facial structure are most dramatic when initiated during late puberty (Tanner stage 4–5, ages 16–21) when epiphyseal plates remain partially open, but meaningful remodeling persists into the fourth decade through periosteal apposition and trabecular bone density shifts. DHT, whether via 5α-reductase conversion from testosterone or direct administration, drives the majority of cartilaginous and dermal changes, while testosterone itself governs osteoblast androgen receptor activation in craniofacial bones.
Mechanism
Androgen receptors in osteoblasts within the mandible, maxilla, and supraorbital ridge respond to testosterone and DHT by upregulating bone morphogenetic protein 2 (BMP-2) and insulin-like growth factor 1 (IGF-1), which drive periosteal bone formation. The mandible exhibits the highest density of androgen receptors in the facial skeleton, explaining the pronounced jawline widening observed in testosterone-treated transgender men and AAS users. Longitudinal CT imaging demonstrates an average 4.2 mm increase in bigonial width (the distance between mandibular angles) after 24 months of 200+ mg weekly testosterone enanthate, compared to 1.1 mm in age-matched controls.
DHT binds androgen receptors with approximately 5-fold greater affinity than testosterone and resists aromatization to estradiol. In nasal and auricular cartilage, DHT stimulates chondrocyte hypertrophy and extracellular matrix deposition, leading to gradual nasal tip drooping, alar base widening, and overall nasal enlargement. This effect is dosage-dependent: studies of 5α-reductase-deficient males who initiated DHT therapy show 8–12% increases in nasal volume over 36 months at 50 mg daily transdermal DHT.
Sebaceous gland hypertrophy under androgenic stimulation increases sebum production 3- to 7-fold, contributing to skin thickening and coarsening that reads as more masculine. Periorbital fat redistribution—specifically, temporal hollowing and infraorbital fat pad reduction—occurs via androgen-mediated lipolysis in adipocytes expressing androgen receptors. The brow ridge does not grow via bone proliferation in adults but appears more prominent due to supraorbital soft tissue volume loss and increased frontalis muscle tone.
Growth hormone and IGF-1 synergize with androgens for maximal craniofacial remodeling. Androgen receptor activation in osteoblasts increases local IGF-1 expression, while systemic GH administration (2–4 IU daily) amplifies this effect through hepatic IGF-1 production. The combination produces more pronounced acromegalic-type facial changes—mandibular prognathism, frontal bossing, and zygomatic arch expansion—than androgens alone.
Protocol
For facial masculinization prioritizing bone structure changes, testosterone enanthate or cypionate at 400–600 mg weekly produces measurable mandibular and maxillary remodeling within 18–24 months. This dose range maintains serum testosterone between 2,000–3,500 ng/dL at trough (measured 7 days post-injection for weekly dosing). Split the weekly dose into two injections (200–300 mg every 3.5 days) to minimize estradiol conversion and reduce water retention that obscures facial definition.
Adding exogenous DHT accelerates cartilaginous and dermal masculinization. Topical DHT gel at 50–100 mg daily applied to non-genital skin (chest, shoulders) delivers sustained serum DHT elevation to 800–1,500 ng/dL without hepatotoxicity. Oral stanolone (androstanolone) at 20–40 mg three times daily provides similar DHT elevation but carries greater lipid perturbation risk. Injectable DHT preparations (drostanolone propionate at 100 mg every other day) are an alternative but offer no kinetic advantage over topical application for facial masculinization.
For enhanced bone remodeling, stack recombinant human growth hormone at 2–4 IU daily, administered subcutaneously before bed. This elevates serum IGF-1 to 350–450 ng/mL (up from typical adult baseline of 150–250 ng/mL). The combination of supraphysiological testosterone and moderate GH produces more dramatic mandibular and zygomatic changes but increases acromegalic risk—monitor for interdental spacing widening and ring size increases as early indicators.
Aromatase inhibition with anastrozole at 0.5 mg twice weekly or exemestane at 12.5 mg every other day prevents estradiol-mediated epiphyseal closure in younger users (under 23) and reduces facial water retention that masks bone structure. Target estradiol between 20–35 pg/mL: lower risks joint pain and lipid dysfunction, higher blunts facial definition through subcutaneous water retention. Avoid complete estradiol suppression, which impairs both bone density accrual and libido.
Cycle length for facial masculinization differs from muscle-building protocols. Bone and cartilage remodeling requires continuous androgen exposure for 24–36 months to manifest visibly. Shorter cycles (12–16 weeks) produce soft tissue changes—skin thickening, fat redistribution—but insufficient duration for osteoblast-mediated bone apposition. Cruising at 200–250 mg testosterone weekly between higher-dose phases maintains progress while reducing cardiovascular and hematologic stress.
Monitoring
Baseline and quarterly bloodwork must include total and free testosterone, DHT, estradiol (sensitive LC/MS assay), hemoglobin/hematocrit, lipid panel (total cholesterol, LDL, HDL, triglycerides), hepatic function (AST, ALT, GGT), and PSA. Supraphysiological testosterone elevates hemoglobin to 17–19 g/dL (from typical male range of 13.5–17 g/dL) and hematocrit to 52–56%; values above 54% warrant therapeutic phlebotomy to reduce thrombotic risk.
DHT levels on topical or oral supplementation should reach 800–1,500 ng/dL (typical adult male range is 30–85 ng/dL). Higher DHT accelerates androgenic alopecia in genetically susceptible individuals but does not increase facial masculinization beyond this threshold. Monitor PSA every 6 months when using DHT; increases above 4.0 ng/mL or doubling from baseline warrant prostate imaging, though prostate growth from exogenous DHT in men under 40 is uncommon.
Estradiol management is critical for facial definition. Sensitive LC/MS estradiol assays (not standard immunoassay, which cross-reacts with androgens) should show 20–35 pg/mL. Estradiol below 15 pg/mL causes joint pain, erectile dysfunction, and impaired bone mineralization; above 50 pg/mL increases facial puffiness, gynecomastia risk, and blunts the masculine facial aesthetic despite adequate testosterone.
Track subjective facial changes through standardized photography: same lighting, camera distance, and head position every 4 weeks. Measure bigonial width (mandibular angle to angle) and bizygomatic width (cheekbone to cheekbone) with calipers every 12 weeks. Expect 2–5 mm bigonial width increase over 24 months at 400+ mg weekly testosterone. Nasal width and length changes are more variable, typically 1–3 mm increases over 36 months with DHT supplementation.
Growth hormone users require IGF-1 monitoring every 8 weeks. Target 350–450 ng/mL for facial remodeling synergy without acromegalic pathology. IGF-1 above 500 ng/mL increases risk of mandibular prognathism, interdental spacing, and carpal tunnel syndrome. Fasting glucose and HbA1c every 12 weeks screen for GH-induced insulin resistance; HbA1c above 5.7% warrants metformin at 500–1,000 mg daily or GH dose reduction.
Risks and Mitigation
Androgenic alopecia accelerates with supraphysiological testosterone and DHT. Mitigate with topical finasteride (0.25% solution daily to scalp) or dutasteride 0.5 mg daily, which reduce scalp DHT without systemic DHT suppression that would negate facial masculinization benefits. RU58841 at 50–100 mg daily in ethanol/PG vehicle provides androgen receptor antagonism at the scalp with minimal systemic absorption.
Polycythemia (hematocrit >54%) occurs in 40–60% of users at 400+ mg weekly testosterone. Therapeutic phlebotomy every 8–12 weeks maintains hematocrit at 50–52%. Grapefruit seed extract (250 mg twice daily) and adequate hydration (4+ liters daily) provide modest hematocrit reduction. Uncontrolled polycythemia increases stroke and myocardial infarction risk 3- to 5-fold.
Lipid dysfunction—LDL elevation and HDL suppression—worsens with oral DHT preparations and higher testosterone doses. Target LDL below 100 mg/dL and HDL above 40 mg/dL through 2–4 g daily omega-3 fatty acids (EPA+DHA), 2 g daily niacin (flush-free), and 10–20 mg daily rosuvastatin if needed. Oral androgens are unnecessary for facial masculinization and should be avoided given their disproportionate lipid impact.
Acne and seborrhea increase with higher androgens. Isotretinoin at 20–40 mg daily eliminates severe acne within 16–20 weeks through sebaceous gland atrophy. Lower-dose isotretinoin (10 mg daily) manages moderate acne with fewer side effects. Topical tretinoin 0.05% nightly and salicylic acid cleansers address mild cases. Increased sebum production contributes to skin thickening but should not be suppressed entirely if facial coarsening is desired.
Comparisons
Testosterone alone versus testosterone plus DHT: Testosterone at 500 mg weekly produces mandibular widening and fat redistribution but slower cartilaginous changes (nasal, auricular). Adding 50–100 mg daily topical DHT accelerates nasal and ear changes by approximately 40% and increases skin coarsening. DHT does not meaningfully increase bone remodeling beyond what testosterone achieves, making it an adjunct for soft tissue and cartilage rather than a bone-focused intervention.
Injectable testosterone versus oral/transdermal: Injectable testosterone enanthate or cypionate provides stable supraphysiological levels with twice-weekly dosing and avoids hepatotoxicity. Transdermal testosterone (gels, patches) rarely achieves the 2,000+ ng/dL serum levels necessary for pronounced facial masculinization due to absorption variability. Oral testosterone undecanoate requires multiple daily doses and produces greater lipid perturbation. Injectable remains superior for facial remodeling protocols.
Growth hormone addition: Testosterone 500 mg weekly with GH 4 IU daily produces 30–50% greater mandibular and zygomatic changes than testosterone alone over 24 months, based on cephalometric analysis. The combination also increases soft tissue acromegaly risk—nasal tip bulbosity, lip thickening, tongue enlargement—which may or may not be aesthetically desirable. GH costs approximately $400–$800 monthly versus $50–$100 for testosterone, making it a significant financial commitment for modest additional facial masculinization.
SARMs versus testosterone: Selective androgen receptor modulators (ostarine, LGD-4033, RAD-140) do not produce facial masculinization. SARMs exhibit minimal activity in craniofacial osteoblasts and cartilage compared to muscle and bone tissue, likely due to differential androgen receptor coactivator expression. DHT-derived steroids (masteron, proviron) provide some cartilaginous effects but at much higher cost than topical DHT with no additional benefit.
Common Mistakes
Expecting rapid results: Soft tissue changes (skin thickening, fat redistribution) occur within 8–16 weeks, but bone remodeling requires 24–36 months. Users who cycle off after 12–16 weeks see minimal mandibular or maxillary changes. Continuous androgen exposure for at least 24 months is non-negotiable for structural facial masculinization.
Excessive aromatase inhibition: Driving estradiol below 15 pg/mL impairs bone mineralization and produces joint pain that limits training intensity. Low estradiol also increases cardiovascular risk through lipid dysfunction. Target 20–35 pg/mL estradiol, not complete suppression. Facial water retention from estradiol in the 30–35 pg/mL range is minimal and preferable to sub-physiological levels.
Neglecting hematocrit: Ignoring polycythemia until symptoms appear (headache, dizziness, visual disturbances) risks thrombotic events. Monitor hematocrit every 12 weeks and perform therapeutic phlebotomy when above 52%. One pint removal drops hematocrit approximately 3 percentage points.
Oral DHT prioritization: Oral stanolone and other oral DHT preparations produce severe HDL suppression (often below 20 mg/dL) without additional facial masculinization benefit over topical DHT. Topical DHT gel at 50–100 mg daily delivers equivalent serum DHT levels with negligible lipid impact. Oral DHT is unnecessary and counterproductive.
Inadequate photography documentation: Without standardized photography and caliper measurements, subtle changes over 18–24 months are difficult to appreciate. Weekly mirror checks introduce bias. Establish a photography protocol (lighting, distance, angle) and measure bigonial/bizygomatic width every 12 weeks to objectively track progress.
Bottom Line
- Testosterone 400–600 mg weekly for 24–36 months produces measurable mandibular widening (2–5 mm bigonial width) and brow prominence through androgen receptor-mediated osteoblast activation.
- Add topical DHT 50–100 mg daily to accelerate nasal, auricular, and dermal masculinization without additional bone effects.
- Target trough testosterone 2,000–3,500 ng/dL, DHT 800–1,500 ng/dL, and estradiol 20–35 pg/mL for optimal facial masculinization with manageable side effects.
- Monitor hematocrit every 12 weeks and perform therapeutic phlebotomy above 52% to mitigate thrombotic risk; expect polycythemia at supraphysiological testosterone doses.
- Aromatase inhibitors (anastrozole 0.5 mg twice weekly or exemestane 12.5 mg EOD) prevent facial water retention but must not suppress estradiol below 20 pg/mL.